GLIPIZIDE-GITS AND METFORMIN ALONE VS COMBINATION THERAPY IN NIDDM

具体目标 1.比较口服降糖药格列吡嗪-Gits和降糖药Glipizide-Gits的降糖效果。 二甲双胍单独或联合应用对小鼠肝脏葡萄糖生成的影响 NIDDM患者。 2.比较高血压患者对舒伐他汀的胰岛素分泌反应 NIDDM接受格列吡嗪-Gits或二甲双胍单独或联合治疗。 这项提议的假设是，口述和口述相结合 一种改善胰岛素分泌的降糖药(格列吡嗪) 改善胰岛素在治疗方案中的作用(二甲双胍) 与任何一种药物相比，NIDDM患者的血糖水平都会得到改善 单独通过协同作用对胰岛素的分泌和作用。

SPECIFIC AIMS 1. To compare the effect of oral hypoglycemic agents Glipizide-GITS and Metformin alone or in combination on hepatic glucose production in patients with NIDDM. 2. To compare insulin secretory responses to Sustacal in patients with NIDDM receiving Glipizide-GITS or Metformin alone or in combination. It is the hypothesis of this proposal that the combination of an oral hypoglycemic agent that improves insulin secretion (Glipizide) with one that improves insulin action (Metformin) in the treatment regiment of NIDDM patients will provide improved glycemia compared to either agent alone through a synergistic effect on insulin secretion and action.